E. Grande, M. Giovannini, E. Marrière
Jul 21, 2020
Citations
0
Influential Citations
7
Citations
Quality indicators
Journal
British Journal of Clinical Pharmacology
Abstract
Capmatinib, an orally bioavailable, highly potent and selective MET inhibitor, was recently approved to treat adult patients with metastatic nonsmall cell lung cancer with METex14 skipping mutations. The study investigated the effect of capmatinib on the pharmacokinetics of a single oral dose of digoxin and rosuvastatin in patients with MET‐dysregulated advanced solid tumours.